Updated:
Eliquent Life Sciences
Eliquent Life Sciences is a life sciences investment firm based in San Francisco, focusing on early- to mid-stage biotechnology and pharmaceutical...
Eliquent Life Sciences
Eliquent Life Sciences operates a life sciences investment platform headquartered in San Francisco. The firm's founding details and principal leadership are not publicly documented, but its name and stated focus suggest a mandate concentrated on biotechnology and pharmaceutical opportunities. The firm targets early- to mid-stage companies developing therapeutics, diagnostics, and related healthcare technologies. Eliquent typically participates in syndicated financings alongside specialist healthcare venture capital firms, often taking minority equity positions. Its portfolio spans preclinical through clinical-stage assets, with a preference for assets addressing large addressable markets. Eliquent does not disclose AUM, total deployment, or the number of investment professionals. No recent operational events from the last 24 months are publicly available. The firm maintains a single office in San Francisco and has no known additional locations or affiliated philanthropic structures. Eliquent Life Sciences represents a focused, sector-specific investment vehicle whose structural differentiator lies in its narrow mandate — it does not diversify beyond life sciences. Its lack of public disclosure on size, team, or portfolio makes external evaluation limited.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
Who manages investment decisions at Eliquent Life Sciences?
Eliquent Life Sciences does not publicly name its investment committee or portfolio managers. No principal names are available from public records or the firm's own disclosures.
What investment stages does Eliquent Life Sciences target?
Based on public reporting, Eliquent Life Sciences focuses on early- to mid-stage life sciences companies, including preclinical and clinical-stage assets. The firm typically participates in syndicated venture rounds.
Does Eliquent Life Sciences invest through funds or direct deals?
Eliquent Life Sciences appears to make direct equity investments in portfolio companies, often co-investing alongside specialist healthcare venture capital firms. The firm may also utilize special purpose vehicles for specific deals.
Which sectors does Eliquent Life Sciences focus on?
The firm concentrates exclusively on life sciences, including biotechnology, pharmaceuticals, and healthcare diagnostics. It does not appear to invest in other sectors such as technology, energy, or real estate.
What is the size of Eliquent Life Sciences?
Eliquent Life Sciences does not disclose its assets under management, number of employees, or total deployment. AUM remains undisclosed in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: